Mourey F, Sureja V, Kheni D, et al. - Saccharomyces cerevisiae variant boulardii CNCM I-3799 (S. boulardii CNCM I-3799) was examined for its efficacy and safety in the management of acute diarrhea in children. Medical care according to the World Health Organization guidelines on the management of acute diarrhea in children was provided to a total of 100 infants and children 3–36 months of age with acute diarrhea and their random allocation was performed to the probiotic group (S. boulardii CNCM I-3799 at a daily dose of 5 billion CFU twice daily) or to the placebo group. Findings support effectiveness of S. boulardii CNCM I-3799 supplementation in children with acute diarrhea in reducing the duration and severity of diarrhea in infants and children.